



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/424,686	
	Filing Date	November 29, 1999	
	First Named Inventor	Gustav Hagen	
	Art Unit	1652	
	Examiner Name	M. Walicka	
Total Number of Pages in This Submission		Attorney Docket Number	Bayer 10,203.1

RECEIVED  
NOV 12 2003  
TECH-CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	<b>-Response to Notice to Comply with Requirements for Patent Application; computer readable Sequence Listing; paper copy of Sequence Listing; Notice to Comply with Requirements for Patent Applic.</b>
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Norris, McLaughlin & Marcus Theodore A. Gottlieb
Signature	
Date	31 October 2003

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the			
Typed or printed name	Agata Glinska		
Signature	Agata Glinska	Date	31 October 2003


This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

11-03-07 41

1652

Atty's Docket Bayer 10,203



**CERTIFICATION OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner For Patents, Washington, D.C. 20231, on October 31, 2003.

Agata Glinska  
Agata Glinska

**RECEIVED**  
NOV 12 2003  
TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

SERIAL NO.	09/424,686
APPLICANT	Gustav HAGEN et al.,
FILED	November 29, 1999
EXAMINER	M. Walicka
ART UNIT	1652
FOR	HUMAN CATALYTIC TELOMERASE SUB-UNIT AND ITS DIAGNOSTIC AND THERAPEUTIC USE

Commissioner of Patents  
PO BOX 1450  
Alexandria, VA 22313-1450

31 October 2003

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE  
AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Sir:

This communication is in response to the Notice mailed on  
6 October August 2003.

In addition to the submissions filed herewith, entry of any amendments and  
consideration of any remarks is respectfully solicited.

IN THE SPECIFICATION

☐ In the above-referenced application, please add the sequence listing filed herewith to the specification.

☒ In the above-referenced application, please substitute the sequence listing filed herewith for the current sequence listing of record in the specification.

In addition, replace pages 15, 27-30, 33, 35, 37-38 of the specification with the replacement pages submitted herewith. The replacement pages have been amended to include the sequence identifiers as required in the most recent notice.

A clean copy and a markup of each replacement page are submitted .

CONDITIONAL PETITION FOR EXTENSION OF TIME

If any extension of time for this response is required, Applicants request that this be considered a petition therefore. Please charge the required fee to Deposit Account No. 14-1263.

ADDITIONAL FEES

Please charge any further insufficiency of fees, or credit any excess to Deposit Account No. 14-1263.

ITEMS BEING SUBMITTED

The checked boxes indicate the items enclosed herewith:

☒ A paper copy of the sequence listing for the nucleotide and/or amino acid sequence(s) in this application, wherein each "Sequence Listing" is assigned a separate identifier as required in 37 CFR 1.821(c) and 37 CFR 1.822 and 1.823.

- ☒ An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 CFR 1.821(d).
- ☒ A copy of each sequence listing submitted for this application in computer readable form, in accordance with the requirements of 37 1.821(e) and 1.824.
- ☒ A statement under 37 CFR 1.821(g) that the content of each paper copy of the sequence listing submitted and each computer readable copy are the same.
- ☒ A statement under 37 CFR 1.821(g) that the submission includes no new matter.
- ☒ A copy of the NOTICE TO COMPLY...SEQUENCE DISCLOSURES.
- ☐ Other (provide description of items submitted)

**STATEMENT THAT SEQUENCE LISTING  
AND COMPUTER READABLE COPY ARE THE SAME  
AND THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER**

I hereby state that each computer readable form submitted in this application, is the same as the paper copy of the "Sequence Listing" to which it is indicated to relate. All papers accompanying this submission, or for which a request for transfer from applicant's other application, introduce no new matter.

Respectfully Submitted,

**Norris, McLaughlin & Marcus**  
220 East 42nd Street  
New York, NY 10017  
Telephone (212) 808-0700  
Facsimile (212) 808-0844

  
Theodore Gottlieb, PhD  
Reg. No. 42, 597